EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte Studie

Management of post-operative pain by metoclopramide in patients undergoing cesarean section: A double-blinded randomized clinical trial

Farshad Hassanzadeh Kiabi, Afshin Gholipour Baradari, Alieh Zamani Kiasari, Goli Aezzi, Sara Malekshah

Journal of Opioid Management · 2026-06-01 · 22 (3) · 269-277

DOI: 10.5055/jom.0955 ↗

At a glance

Randomisierte kontrollierte Studie in Journal of Opioid Management, published online on 2026-06-01. Written by Farshad Hassanzadeh Kiabi and 4 co-authors. Institution: Mazandaran University of Medical Sciences, Sari, Iran. Major MEDLINE topics: Metoclopramide, Cesarean Section, Postoperative Pain, Dopamine Antagonists.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Objective

Poor post-operative pain management after cesarean section (C-section) can have adverse effects on the mother and baby and is associated with increased opioid intake. This study aims to evaluate the effects of the dopamine antagonist, metoclopramide, on the management of post-operative pain among women undergoing elective C-sections.

Method

This double-blinded randomized study included women who underwent C-sections at our center. The patients were divided into an intervention group and a control group. The intervention group received 20 mg metoclopramide, whereas the control group was given 2 cc of distilled water as a placebo, intravenously, post-operatively, before the closing of the surgical site. At 2, 4, 6, 8, 12, and 24 postoperative hours, data regarding pain (measured via a visual analog scale), nausea and vomiting, and resumption of physical activity were obtained along with the demographic information of the patients.

Results

Fifty patients were included in both groups. The mean age, body mass index, number of previous deliveries, education, smoking status, and number of previous C-sections were not significantly different between the two groups. Metoclopramide reduced early post-cesarean pain (Visual Analog Scale [VAS]: 7.38 vs 8.48 at 2 hours, *p < 0.001) and morphine use (18.7 mg vs 22.3 mg, *p = 0.032), with transient antiemetic effects at 2 hours. The mean VAS scores at 2 and 4 post-operative hours were significantly different between both groups, respectively. The incidence of nausea and vomiting was significantly different at the second post-operative hour only.

Conclusion

Metoclopramide significantly reduced early post-operative pain and opioid requirements, with reductions exceeding minimal clinically important difference thresholds. While statistically robust, these benefits should be weighed against its transient antiemetic effects and the need for larger trials to confirm functional recovery benefits.

Subjects

MeSH terms (MEDLINE)

MetoclopramideCesarean SectionPostoperative PainDopamine AntagonistsHumansFemaleDouble-Blind MethodAdultPregnancyPain MeasurementPostoperative Nausea and VomitingAnalgesics, OpioidTreatment OutcomeTime Factors

Substances

MetoclopramideDopamine AntagonistsAnalgesics, Opioid

Authors and institutions

  • Mazandaran University of Medical Sciences, Sari, Iran.

Cite

APA

Kiabi, F. H., Baradari, A. G., Kiasari, A. Z., Aezzi, G., & Malekshah, S. (2026). Management of post-operative pain by metoclopramide in patients undergoing cesarean section: A double-blinded randomized clinical trial. Journal of Opioid Management, 22(3), 269-277. https://doi.org/10.5055/jom.0955

Vancouver

Kiabi FH, Baradari AG, Kiasari AZ, Aezzi G, Malekshah S. Management of post-operative pain by metoclopramide in patients undergoing cesarean section: A double-blinded randomized clinical trial. Journal of Opioid Management. 2026;22(3):269-277. doi:10.5055/jom.0955

BibTeX
@article{Kiabi2026,
  author = {Kiabi, Farshad Hassanzadeh and Baradari, Afshin Gholipour and Kiasari, Alieh Zamani and Aezzi, Goli and Malekshah, Sara},
  title = {Management of post-operative pain by metoclopramide in patients undergoing cesarean section: A double-blinded randomized clinical trial},
  journal = {Journal of Opioid Management},
  year = {2026},
  volume = {22},
  number = {3},
  pages = {269--277},
  doi = {10.5055/jom.0955}
}
Start for free →